LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
NOVARTIS AG : Gets a Buy rating from UBS ZD
EXECUTIVE CHANGES: Invinity replaces CEO; Gulf Keystone chair dies AN
Veeva Systems: leader in cloud solutions for the life sciences industry Our Logo
NOVARTIS : Goldman Sachs no longer Buy CF
Such a long wait Our Logo
Goldman Sachs Downgrades Novartis to Neutral From Buy, Adjusts Price Target to $121 From $119 MT
Novartis shares fall back as Morgan Stanley takes a break CF
Voyager Therapeutics Gets Capsid License for Gene Therapy Program From Novartis MT
Goldman Sachs Downgrades Novartis to Neutral, Trims PT MT
EDX Medical Group Names New Chief Commercial Officer MT
NOVARTIS AG : Goldman Sachs is Neutral ZD
Novartis Starts Construction of New Radioligand Therapy Sites in US MT
Novartis: two new radioligand units in the USA CF
NOVARTIS : Jefferies upgrades to 'hold', share price consolidates CF
Jefferies Downgrades Novartis to Hold, Lowers PT MT
Jefferies Downgrades Novartis to Hold From Buy MT
US will still pay at least twice as much after negotiating drug prices RE
NOVARTIS AG : From a Buy to Neutral rating by Jefferies ZD
Siemens Healthineers wants to expand nuclear diagnostics with acquisition RE
Bayer: new CEO for Bayer HealthCare in France CF
Stocks Edge Up Amid Swiss Rate Cut Optimism MT
European Equities Close Mostly Higher in Wednesday Trading; Incoming HSBC CEO Mulls Staff Cuts MT
Novartis: strategic collaboration with Lindy Biosciences CF
Novartis Gains Exclusive Rights to Lindy Biosciences' Drug Delivery Technology MT
Novartis, Lindy Biosciences Sign Deal for Subcutaneous Injection Technology MT
Chart Novartis AG
More charts
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Employees
76,057
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
115.32USD
Average target price
116.54USD
Spread / Average Target
+1.06%
Consensus
  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. News Novartis AG
  5. Novartis Gets US FDA's Priority Review for Chronic Myeloid Leukemia Drug
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities. Last hours!
BENEFIT NOW